ArticleAnnals of hematology2025

VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML.

Lydia Kretschmer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.